KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Revenue (2016 - 2025)

Historic Revenue for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $1.2 billion.

  • Alnylam Pharmaceuticals' Revenue rose 14934.69% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 2630.74%. This contributed to the annual value of $2.2 billion for FY2024, which is 2296.96% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Revenue stood at $1.2 billion, which was up 14934.69% from $773.7 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Revenue high stood at $1.2 billion for Q3 2025, and its period low was $30.0 million during Q1 2025.
  • For the 5-year period, Alnylam Pharmaceuticals' Revenue averaged around $421.6 million, with its median value being $319.3 million (2023).
  • Its Revenue has fluctuated over the past 5 years, first surged by 18396.25% in 2023, then crashed by 9393.12% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Revenue stood at $258.5 million in 2021, then rose by 29.59% to $335.0 million in 2022, then surged by 31.25% to $439.7 million in 2023, then skyrocketed by 34.9% to $593.2 million in 2024, then surged by 110.57% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $773.7 million for Q2 2025, and $30.0 million during Q1 2025.